[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pet-scan\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pet-scan":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370",false,"NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","ALL","2 Years","35 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[28,29,30,31,32,33,34,35,36],"Classical Hodgkin Lymphoma","Child","Adolescent","Young Adult","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan","RECRUITING","2026-03-17",{"date":40,"type":41},"2026-03-19","ACTUAL",{"date":43,"type":41},"2024-09-25",{"date":45,"type":21},"2039-11-15",{"name":47,"class":48},"Children's Cancer Group, China","NETWORK",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":17,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100576961","ga-68-dolacga-pet-scan-in-hcc-under-rfa-100576961","NCT06792097","Ga-68 Dolacga PET Scan in HCC Under RFA","The Role of Ga-68 Dolacga PET Scan in Patients With Hepatocellular Carcinoma Under Radiofrequency Ablation","HCC; RFA","Inclusion Criteria:\n\n* Patients with hepatocellular carcinoma (BCLC stage 0 and stage A) eligible for radiofrequency ablation (RFA) treatment exhibit the following characteristics:\n\n  1. A single liver tumor, ≤ 2 cm, classified as BCLC stage 0 (very early stage).\n  2. Tumors ≤ 3 in number, each ≤ 3 cm, or a single tumor ≤ 5 cm, classified as BCLC stage A (early stage) liver cancer.\n  3. ECOG performance status of 0.\n  4. Age ≥ 18 years.\n\n     Exclusion Criteria:\n* Intermediate (BCLC B stage) and advanced (BCLC C stage) liver cancer patients:\n\n  1. A single tumor \\> 5 cm, or multiple tumors \\> 3 cm.\n  2. Diffuse hepatocellular carcinoma.\n  3. Vascular invasion (e.g., portal vein obstruction).\n  4. Extrahepatic tumor spread.\n* Early-stage liver cancer (BCLC A stage):\n\n  1. Contraindications for radiofrequency ablation (RFA).\n  2. Target lesions previously treated with local therapies, including surgical resection, percutaneous ethanol injection (PEI), or liver transplantation.","18 Years","80 Years",{"count":61,"type":21},10,"OBSERVATIONAL","This study aims to investigate the use of Ga-68 Dolacga PET scan technology to assess treatment response and liver function changes in patients of early-stage liver cancer receiving RFA. The main questions it aims to answer are:\n\n1. How to assess treatment response and liver function changes in hepatocellular carcinoma patients undergo RFA via Ga-68 Dolacga PET scan?\n2. Compared with computed tomography (CT) scans, how effective is Ga-68 Dolacga PET scan for treatment response assessment?\n3. What is the correlation between Ga-68 Dolacga PET scan findings and patient treatment outcomes by tracking liver function and tumor recurrence after RFA?\n\nParticipants will:\n\n1. Undergo Ga-68 Dolacga PET scans and computed tomography before and one month after RFA treatment, followed by monitoring every three months thereafter.\n2. Total liver functional volume and residual liver functional volume are obtained from Ga-68 Dolacga PET scan",[65,66,36,67,68],"Hepatocellular Carcinoma (HCC)","Radiofrequency Ablation","Computed Tomography","Deep Learning",[70,71,72,73,74,75],"Hepatocellular carcinoma","Radiofrequency ablation","Ga-68 Dolacga PET scan","Liver function","Neural network","Radiomics","NOT_YET_RECRUITING","2025-01-19",{"date":79,"type":41},"2025-01-24",{"date":81,"type":21},"2025-02-01",{"date":83,"type":21},"2026-12-31",{"name":85,"class":86},"National Taiwan University Hospital","OTHER"]